Prolonged Serum Levodopa Levels With Controlled-Release Carbidopa-Levodopa in the Treatment of Parkinson‧s Disease
- J. Thomas Hutton(corresponding author),
- J. William Albrecht,
- Gustavo C. Román,
- Michael T. Kopetzky
- Texas Tech University Health Sciences Center,
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewAbstract
<p>Twenty parkinsonian patients (Hoehn and Yahr scale, I through III) were treated with controlled-release carbidopa-levodopa (CR-2 or CR-3) and standard carbidopa-levodopa (Sinemet, 25 mg/100 mg) in a double-blind, crossover pharmacokinetic and clinical efficacy study. The controlled-release agents had a slower rise to peak plasma values and flatter pharmacokinetic curves than did the standard. The area under the curve for CR-3 was significantly increased by 55.5% as compared with standard agent and by 84.2% as compared with CR-2. No differences in clinical efficacy were found between controlled-release agents and the standard agent for this group of parkinsonian patients with mild to moderate severity. The dissociation between the prolonged serum levodopa levels and unimproved clinical efficacy may have resulted from the absence of patients with prominent motor fluctuations and/or substantial serum levodopa variability that was especially prominent with CR-3.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 55-57 (3 pages)Journal (Volume, Issue Number)
Archives of Neurology (Volume 45, Issue 1)Publication milestones
- Published - 01/1988
Publication status
Published - 01/1988
ISSN
0003-9942Publication IDs
- Scopus: 0023864321
- PubMed: 3276299
Publication metrics
Metrics
Fractional count
1
Fractional count
0.25
Fractional count
3
Fractional count
0.75
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Captures
10
Citation count
10
